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Fibromyalgia (FM) is a chronic disorder characterized by multifocal pain and other associated 
somatic symptoms including fatigue, insomnia, cognitive/memory problems, and even 
psychological distress. It appears that 2–4% of the general population suffers from FM. FM 
negatively impacts the physical functioning of its patients, as evidenced by difficulties with 
multiple daily activities, as well as affecting emotional health, social functioning, and health 
related quality of life. This review will discuss the potential theories that possibly contribute to 
the pathogenesis of FM, although the precise mechanism is unknown. The evolution of the 
assessment of FM will also be examined, with the waning use of tender point examinations 
and the appearance of new simple, practical diagnostic criteria. Although non-pharmacologic 
therapeutic options (exercise, education, cognitive–behavioral therapy) have been shown to 
be extremely effective in FM, the focus of this article will be on pharmacologic strategies. 
Non-Food and Drug Administration (FDA) approved as well as FDA approved agents will be 
presented. Each agent’s therapeutic “niche” in FM management will be discussed based on 
its pharmacologic profile, patient responsiveness, and tolerability. Finally a clinical algorithm will 
be presented for the step-wise management of pain and other associated symptoms of FM.
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for these syndromes [e.g., chronic fatigue syndrome, vulvodynia/
chronic pelvic pain, IBS, interstitial cystitis, temporomandibular 
disorder (TMD), FM].
Groups of individuals with these CSS conditions (e.g., FM, 
IBS, interstitial cystitis, headaches, TMD, etc.) display diffuse 
hyperalgesia (increased pain in response to normally painful 
stimuli) and/or allodynia (pain in response to normally non-
painful stimuli; Langemark et al., 1989; Maixner et al., 1995; 
Clauw et al., 1997; Giesecke et al., 2004, 2005; Ness et al., 2005; 
Rodrigues et al., 2005). Many of these conditions have also been 
shown to demonstrate more sensitivity to many stimuli other 
than pain (i.e., auditory, Gerster and Hadj-Djilani, 1984; Geisser 
et al., 2007, visual), and the aggregate data suggest that these 
individuals have a fundamental problem with pain or sensory 
amplification rather than an structural or inflammatory condi-
tion in the specific body region where the pain is being experi-
enced (Smith et al., 2011).
Non-pharmacologic therapeutic options are extremely 
important in the management of this disorder, however we will 
briefly touch upon this aspect of treatment as pharmacologic 
strategies are the focus of this article. In this narrative review 
of the current available literature, the authors each separately 
performed a review using MEDLINE/PubMed, and EMBASE 
as sources in a non-systematic fashion and search terms (FM, 
pathophysiology, treatment, criteria). Abstracts were screened 
for relevance with additional sources identified via manual 
search of bibliographies and reference lists. The searches were 
restricted to the English language. Observational studies (e.g., 
cohort and case control studies) and open-label studies were 
excluded from the review.
INTRODUCTION
Fibromyalgia (FM) is a central pain disorder that seems to involve 
altered afferent processing, resulting in augmentation of periph-
eral stimuli, especially the nociceptive types. The “core” symptoms 
seen in FM and many other central sensitization disorders include 
multifocal pain, fatigue, insomnia, cognitive/memory problems, 
and psychological distress. However, FM patients may experience a 
multitude of other symptoms, including dysesthesias, stiffness, poor 
balance, oral/ocular symptoms (e.g., keratoconjunctivitis sicca), 
headaches, sexual dysfunction, and impaired physical function 
(Figure 1).
Chronic widespread pain (CWP) may occur with no other asso-
ciated symptoms, generally referring to persistent pain ≥3 months 
with multiple locations in multiple extremities (usually upper and 
lower/right and left side of body), spine/axial skeleton, head, and/
or thoraco abdominopelvic regions. FM includes CWP, but also 
includes other symptoms, notably fatigue, sleep disturbance, stiff-
ness, hyperalgesia, impaired functioning, and cognitive or memory 
problems.
There is growing support that FM is part of a much larger con-
tinuum that has been called many things, including functional 
somatic syndromes, medically unexplained symptoms, chronic 
multisymptom illnesses, somatoform disorders, and perhaps most 
appropriately, central sensitivity syndromes (CSS; Smith et al., 
2011). Yunus (1984) showed FM to be associated with tension type 
headache, migraine, and irritable bowel syndrome (IBS). There 
may be a fair amount of clinical overlap between these syndromes. 
The more recent term CSS as proposed by Yunus (2008) is the pre-
ferred term to globally group these entities together in, because it 
is felt that this may represent the best nosological term at present 
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FIBROMYALGIA SYNDROME
It appears that 2–4% (Wolfe et al., 1995; Miedema et al., 1998) of 
the population suffers from FM, with the disorder being two times 
more prevalent among women than men. This latter statement 
may be attributed to the fact that women tend to be more tender 
than men. The disorder is predominantly diagnosed in patients 
aged 20–60 years (mean age, 49 years; Wolfe et al., 1995; Miedema 
et al., 1998). FM negatively impacts the physical functioning of its 
patients, as evidenced by difficulties with multiple daily activities 
(Bennett et al., 2007; Jones et al., 2008). Sixty-two percentage of 
patients have difficulty climbing stairs, 55% have difficulty walk-
ing two blocks, and 35% have difficulty with activities of daily life 
(ADLs; Bennett et al., 2007). FM can also negatively affect personal 
relationships, career, and mental health (Bernard et al., 2000).
PAThOPhYSIOLOGY OF FIBROMYALGIA
A quantitative sensory testing study in 85 FM patients and 40 matched 
controls found that the patients had altered heat and cold thresholds 
and a reduced tolerance for pain, as well as a reduced nociceptive 
reflex threshold, a measure of central excitability (Desmeules et al., 
2003). There appears to be significant support for central sensiti-
zation in the generation of FM symptoms (Burgmer et al., 2009; 
Woolf, 2011). Staud et al. (2001) showed temporal summation and 
after sensations of the pain elicited by repetitive cutaneous thermal 
stimuli and repetitive mechanical stimuli to muscles in patients 
with FM. Two years later, Staud et al. (2003a) found that temporal 
summation occurred at substantially lower forces and at a lower 
frequency of stimulation in FM patients than in control subjects, and 
that painful after sensations were greater in amplitude and more pro-
longed. The enhanced experimental pain in FM patients was shown 
to contribute to the variance of the clinical pain (Staud et al., 2003b). 
The year after Staud et al. (2004) showed that the maintenance of 
experimentally induced pain in FM patients requires significantly 
less frequent stimulation than in normal controls, and concluded 
that this heightened sensitivity to very low frequency inputs con-
tributes to the persistent pain in these patients. Staud et al. (2007) 
demonstrated 3 years later that the temporal summation of pain and 
its maintenance was widespread, and could be equally elicited from 
hands or feet, leading to the conclusion that central sensitization in 
these patients was generalized across the neuraxis. Staud et al. also 
concluded that enhanced neural mechanisms in FM are not the 
result of selective enhancement at cortical levels (Staud et al., 2008a) 
and peripheral sensitization does not significantly contribute to the 
enhanced temporal summation of thermal pain in FM patients, 
based on thermal thresholds (Staud et al., 2008b).
Although there is no direct evidence, it is hypothetically conceiv-
able that microglial activation may contribute to FM pathophysiology 
(Smith, 2009; Younger and Mackey, 2009). Microglial activation could 
lead to thalamic changes (Pattany et al., 2002; Zhao et al., 2007) with 
resultant abnormal processing of ascending input in FM (Smith, 2009). 
Thalamic changes in FM appear to be supported by neuroimaging 
studies (Burgmer et al., 2009; Diers et al., 2011) and altered thalamic 
blood flow present in chronic pain states may normalize upon pain 
relief (Di Piero et al., 1991; Hsieh et al., 1996). Microglial activation 
coupled with thalamic changes may trigger neuronal hyperexcitabil-
ity which in conjunction with diminished or inefficient descending 
inhibitory pathways in FM [as evidenced by reduced diffuse noxious 
inhibitory controls (DNIC) in FM patients; Staud et al., 2003c; de 
Souza et al., 2009; Normand et al., 2011; or the now “preferred” term 
in place of DNIC, conditioned pain modulation (CPM); Yarnitsky, 
2010; Yarnitsky et al., 2010], may lead to central sensitization with 
the subsequent development of chronic pain (Smith, 2009).
The precise mechanisms responsible for FM are unknown, 
but most likely involve alterations in pain and sensory processing 
systems. In particular, it is thought that patients with FM have 
inefficient descending inhibitory pathways, which normally func-
tion as endogenous analgesic systems to ameliorate pain in healthy 
subjects. These descending inhibitory pathways are mediated in part 
by the neurotransmitters serotonin and norepinephrine (Figure 2).
Studies demonstrate that patients with FM have lower cerebro-
spinal fluid (CSF) levels of metabolites of biogenic amines (e.g., 
serotonin and norepinephrine; Russell et al., 1992). Further evi-
dence comes from treatment studies which reveal that any agent 
that simultaneously raises both serotonin and norepinephrine [e.g., 
tricyclic antidepressants (TCAs), duloxetine, milnacipran, trama-
dol] has been shown to be efficacious in treating FM.
In addition both the subunit genes of the serotonergic receptors, 
HTR3A and HTR3B, have been assessed for variations in sequence 
in FM patients (Coaccioli et al., 2008). However, statistical analy-
sis determined that the various polymorphisms are probably not 
correlated to the disorder (Coaccioli et al., 2008). Polymorphisms 
in catechol-O-methyltransferase, the enzyme that inactivates cat-
echolamines, have also been recently examined for importance in 
FM (Gürsoy et al., 2003). Low activity COMT genotype (LL) and 
intermediate activity COMT genotype (LH) were both more fre-
quently found in FM (Gürsoy et al., 2003).
Dysregulation of dopaminergic neurotransmission has been 
proposed to potentially play a part in FM pathogenesis (Coaccioli 
et al., 2008). The pain-suppression system, activated by an acute 
stress, is mediated by activation of the mesolimbic dopamine 
neurons arising from the cell bodies of the ventral tegmental area 
and projecting to the nucleus accumbens (Coaccioli et al., 2008). 
It is proposed that exposure to prolonged stress produces both 
a reduction in dopamine output from the nucleus accumbens 
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Smith et al. Pharmacotherapy for fibromyalgia
Frontiers in Pharmacology | Neuropharmacology  March 2011 | Volume 2 | Article 17 | 2
regions exhibiting increased activity included the primary and sec-
ondary somatosensory cortex, the insula, and the anterior cingulate 
cortex, all areas which exhibit increased blood flow when normal 
subjects experience pain (Gracely et al., 2002).
Although it appears that the predominant mechanisms contrib-
uting to FM are largely central in nature; there may be peripheral 
mechanisms at play as well. Multiple studies have demonstrated 
differences in skin biopsies of FM patients vs. healthy controls 
(Kim et al., 2008) including: ballooning of Schwann cells (Kim 
et al., 2008), mitochondrial abnormalities (Cordero et al., 2010), 
and abnormal over expression of mastocytes (Blanco et al., 2010). 
Affaitati et al. (2011) revealed that identification and local targeted 
treatment of “peripheral pain generators” in the myofascial con-
nective tissues or joints which coexisted in some patients with FM, 
resulted in significant benefit of the CWP of FM. Staud published 
that FM pain is likely to be at least partially maintained by periph-
eral impulse input from deep tissues, since injection of local anes-
thetics into painful muscles normalizes somatic hyperalgesia in FM 
patients (Staud et al., 2009; Staud, 2010).
DIAGNOSIS AND ASSESSMENT OF FIBROMYALGIA
The American College of Rheumatology (ACR) criteria require that 
an individual possess both a history of CWP and ≥11 of 18 possible 
tender points on physical examination. However, these criteria are 
used predominantly for research/epidemiologic purposes. The use 
of tender points as diagnostic criteria is beginning to fade as it 
fails to recognize the presence of other symptoms that need to be 
addressed to optimally manage FM patient (Carville et al., 2008). 
Wolfe (2003) conducted a study in which they mailed surveys to 
12,799 patients with either RA, osteoarthritis (OA), or FM. They 
found that pain present in 19 primarily non-articular sites differen-
tiated FM from the other two disorders (Wolfe, 2003; Wilke, 2009).
and the development of persistent hyperalgesia (Coaccioli et al., 
2008). A pilot study examined this theory, demonstrating reduced 
presynaptic dopamine activity in FM patients using positron 
emission tomography with 6-18-fluoro-l-DOPA as a tracer 
(Wood et al., 2007).
Another mechanism thought to play a role in the pathophysiol-
ogy of FM is the presence of augmented pain pathways in these 
patients. These pathways are mediated in part by substance P and 
the excitatory amino acid glutamate (Xu et al., 1992). Studies dem-
onstrate that patients with FM have significantly higher concentra-
tions of substance P in CSF compared with healthy subjects (Vaerøy 
et al., 1988; Russell et al., 1994; Bradley et al., 1996; Bradley and 
Alarcón, 1999; Lui et al., 2000). CSF levels of glutamate are also 
twice as high in patients with FM compared with healthy controls 
(Sarchielli et al., 2007a). Furthermore, levels of the neurotrophic 
factors brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF) were increased in CSF of FM patients, but 
was not found to be specific to FM (also found in patients with 
chronic migraine; Sarchielli et al., 2007b).
Other biological abnormalities exist in FM, with possible rel-
evance to its pathophysiology. In particular, anti-inflammatory 
cytokines were found to be decreased in FM patients, indicating 
that low levels of these protective cytokines could potentially be a 
risk factor for FM (Uçeyler et al., 2006). Interestingly, multi-modal 
pain therapy appears to modify cytokine profiles in FM (Wang 
et al., 2008).
Brain imaging studies also support the existence of central pain 
augmentation in patients with FM (Gracely et al., 2002). Gracely 
et al. (2002) performed a study utilizing functional MRI (fMRI) in 
patients with FM in 2002. When stimuli of equal magnitude were 
administered to both FM and healthy subjects, there was increased 
regional blood flow in FM patients compared with controls. The 
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in that it has modified function questions and includes questions 
pertaining to memory, tenderness, balance, and environmental 
sensitivity. All questions are graded on a 0–10 numerical scale 
(Table 1).
Each of the three domains of the FIQR correlated well with the 
related domains of the FIQ (r = 0.69–0.88, p < 0.01). The total scores 
of the FIQR and the FIQ were also closely correlated (r = 0.88, 
p < 0.001). There was good correlation between the FIQR and 
comparable domains in the Medical Outcomes Study Short Form 
36 (SF-36), with a multiple regression analysis showing that the 
three FIQR domain scores predicted the eight SF-36 subscale scores 
(Bennett et al., 2009b).
NON-PhARMACOLOGIC TREATMENT OF FIBROMYALGIA
Non-pharmacologic approaches such as exercise, education, and 
cognitive–behavioral therapy (CBT) have a positive impact in FM, 
but it is felt that these treatments appear to be underutilized in usual 
clinical practice (Williams, 2005; Chou et al., 2007).
Several studies have shown that exercise is beneficial in FM 
patients, especially with respect to reducing physical symptoms 
and improving functional capacity (Jones and Liptan, 2009). 
Exercise modalities studied included land and water aerobics, 
strength training, flexibility training, and various combinations 
of these (Jones and Liptan, 2009). The strongest evidence dem-
onstrating benefit in FM is for aerobic and mixed-type exercises, 
with growing evidence for positive effects from strength training 
(Jones et al., 2002; Figueroa et al., 2008; Valkeinen et al., 2008; 
Thomas and Blotman, 2010). Busch et al. (2008) systematically 
reviewed 34 studies assessing the efficacy of exercise in FM. Meta-
analysis of six of those studies provided moderate-quality evi-
dence that aerobic-only exercise at intensity levels recommended 
by the American College of Sports Medicine has positive effects 
on global-well-being, physical functioning, and potentially on 
pain (Busch et al., 2008).
Patient education has also been analyzed as a therapeutic option 
for FM patients. Rooks et al. (2007) completed a randomized 
controlled trials (RCT) with 207 participants with FM who were 
randomized to four groups: (1) aerobic and flexibility training 
group; (2) strength, aerobic, and flexibility training group; (3) the 
Fibromyalgia Self-Help Course; or (4) a combination of the previ-
ous three. The combination group was found to provide the most 
benefit (Rooks et al., 2007). Thus, education may be useful for 
FM patients when utilized with other multi-modal interventions.
Cognitive–behavioral therapy combines aspects of both cogni-
tive and behavioral interventions. Catastrophic thoughts, which are 
beliefs that the worst possible outcome is going to occur, is associ-
ated with increased pain severity, reduced functional capacity, and 
affective distress in FM patients (Giesecke et al., 2005). Cognitive 
therapy focuses on taking catastrophic thoughts and refram-
ing them into more positive beliefs (Hassett and Gevirtz, 2009). 
Behavioral therapy, in contrast, stresses the importance of operant 
behavioral change over inner thoughts and feelings (Hassett and 
Gevirtz, 2009). Its goals are to increase adaptive behavior through 
positive and negative reinforcement, and to extinguish maladaptive 
behavior through punishment (Hassett and Gevirtz, 2009). Studies 
have demonstrated that both OBT and CBT are effective modalities 
in treating FM (Thieme et al., 2006; Thieme and Gracely, 2009).
This study led to the proposal of new simple, practical criteria 
for the clinical diagnosis of FM. Through a multicenter study of 
829 previously diagnosed FM patients and controls, the authors 
were able to develop a case definition of FM, develop criteria, 
and construct a symptom severity (SS) scale (Wolfe et al., 2010). 
Interestingly approximately 25% of FM patients did not satisfy 
the ACR criteria at the time of the study. The most important 
diagnostic variables were found to be the widespread pain index 
(WPI; a measure of the number of painful body regions) and cat-
egorical scales for cognitive symptoms, unrefreshed sleep, fatigue, 
and other somatic symptoms. The categorical scales were summed 
to create an SS scale (Wolfe et al., 2010). A new case definition of 
FM was developed by combining the WPI and SS scale: (WPI ≥ 7 
and SS ≥ 5) or (WPI 3–6 and SS ≥ 9; Wolfe et al., 2010). This new 
case definition of FM correctly classifies 88.1% of cases classified 
by the ACR criteria, without the use of a physical or tender point 
examination. The SS scale enables assessment of SS in currently or 
previously diagnosed FM patients, and may potentially be useful 
in the longitudinal evaluation of patients with marked symptom 
variability (Wolfe et al., 2010). It is important to note that these 
new criteria are certainly not meant to supplant the concept of a 
tender point or to not establish the presence of multifocal tender-
ness/mechanical hyperalgesia by a thorough physical examination.
The new American College of Rheumatology (ACR) criteria 
accomplish the following: remove tender points from the criteria 
and as the central element in the FM definition; change the case 
definition of FM; recognize the importance of a quantitative meas-
ure of widespread pain, the WPI; incorporate key FM symptoms 
into the criteria; and provide severity scales to measure the extent 
of widespread pain and SS (Wolfe, 2010). The new ACR criteria 
replace the 11 tender point dichotomy as well as the widespread 
pain dichotomy with the continuous WPI scale that provides much 
more information about pain threshold and pain extent (Wolfe, 
2010). The new ACR criteria introduced the SS scale, which is a 
summary score from scales measuring the extent of fatigue, unre-
freshed sleep, cognitive problems, and multiplicity of symptoms. 
The SS score correlates with the WPI at 0.733 and the tender point 
count at 0.680, and is used as part of new FM criteria (Wolfe, 2010).
The Fibromyalgia Impact Questionnaire (FIQ) is a validated, 
disease-specific composite measure that was developed to deter-
mine the range of symptoms experienced by FM patients and 
responses to therapy (Bennett, 2005). It was updated in 1997 and 
2002 to reflect experience with using the instrument and to clarify 
the scoring system (Bennett, 2005). It includes 20 questions that 
assess functionality with ADLs, work difficulty, general feelings of 
well-being, sleep quality, and the severity of symptoms including 
pain, fatigue, depression, anxiety, and stiffness (Bennett, 2005). 
Bennett et al. (2009a) performed an analysis which demonstrated 
that a 14% change in the FIQ total score represented a statistically 
and clinically meaningful difference for the patient. The results of 
this analysis should enhance the utility of the FIQ for clinical and 
research purposes (Bennett et al., 2009a).
The Revised Fibromyalgia Impact Questionnaire (FIQR) is an 
updated version of the FIQ that has good psychometric proper-
ties, is easy to score, and can be completed in less than 2 min 
(Bennett et al., 2009b). It has the same three domains as the FIQ: 
function, overall impact, and symptoms. It differs from the FIQ 
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PhARMACOLOGIC TREATMENT OF FIBROMYALGIA
The majority of clinical trials evaluating FM therapy have included 
antidepressants of one class or another, especially the older, TCAs. 
Amitriptyline is a TCA tertiary amine with prominent therapeutic 
effects from monoamine reuptake (serotonin > norepinephrine) 
and anticholinergic/sedative side effects mediated by receptor affin-
ity at acetylcholine, muscarinic, and histamine 1 receptors (Smith 
and Barkin, 2010; Figure 3).
Its usual half-life is 31–46 h, and its metabolism is through 
CYP450 2C19, 1A2, and 2D6 (Smith and Barkin, 2010).
Uçeyler et al. (2008) performed a meta-analysis on the effi-
cacy of antidepressants for treating FM. The authors found 
amitriptyline, studied in 13 RCTs, to provide a moderate mag-
nitude of relief to FM patients (pain reduction by mean of 26%, 
improvement in QOL by 30%; Uçeyler et al., 2008).
Bernardy et al. (2010) recently performed the first meta-anal-
ysis of the efficacy of CBT in FM. The systematic review included 
14 out of 27 studies with 910 subjects and a median treatment 
time of 27 h over a median time range of 9 weeks. The primary 
endpoints were pain, sleep, fatigue, and health related quality of 
life (HRQOL). Secondary endpoints included depressed mood, 
self-efficacy pain, and healthcare-seeking behavior (Bernardy 
et al., 2010). They demonstrated that CBT reduced depressed 
mood and self-efficacy pain post-treatment, but had no signifi-
cant effects on pain, fatigue, sleep, or HRQOL after treatment 
or at follow-up. Furthermore, OBT was shown to significantly 
reduce the number of physician visits at follow-up. Thus CBT 
may be most beneficial in helping FM patients cope with pain 
and depression on their own and somewhat reduce dependence 
on health care providers (Bernardy et al., 2010).
Table 1 | revised Fibromyalgia impact Questionnaire (FiQr).
Domain 1 directions: for each of the following nine questions, check the one box that best indicates how much your fibromyalgia made it difficult 
to do each of the following activities over the past 7 days
Brush or comb your hair No difficulty o o o o o o o o o o o Very difficult
Walk continuously for 20 min No difficulty o o o o o o o o o o o Very difficult
Prepare a homemade meal No difficulty o o o o o o o o o o o Very difficult
Vacuum, scrub, or sweep floors No difficulty o o o o o o o o o o o Very difficult
Lift and carry a bag full of groceries No difficulty o o o o o o o o o o o Very difficult
Climb one flight of stairs No difficulty o o o o o o o o o o o Very difficult
Change bed sheets No difficulty o o o o o o o o o o o Very difficult
Sit in a chair for 45 min No difficulty o o o o o o o o o o o Very difficult
Go shopping for groceries No difficulty o o o o o o o o o o o Very difficult
Domain 2 directions: for each of the following two questions, check the one box that best describes the overall impact of your fibromyalgia over 
the past 7 days
Fibromyalgia prevented me from Never o o o o o o o o o o o Always 
accomplishing goals for the week
I was completely overwhelmed by Never o o o o o o o o o o o Always 
my fibromyalgia symptoms
Domain 3 directions: for each of the following 10 questions, check the one box that the best indicates the intensity of your fibromyalgia symptoms 
over the past 7 days
Please rate your level of pain No pain o o o o o o o o o o o Unbearable pain
Please rate your level of energy Lots of energy o o o o o o o o o o o No energy
Please rate your level of stiffness No stiffness o o o o o o o o o o o Severe stiffness
Please rate the quality of your sleep Awoke rested o o o o o o o o o o o Awoke very tired
Please rate your level of depression No depression o o o o o o o o o o o Very depressed
Please rate your level of memory problems Good memory o o o o o o o o o o o Very poor memory
Please rate your level of anxiety No anxious o o o o o o o o o o o Very anxious
Please rate your level of tenderness to touch No tenderness o o o o o o o o o o o Very tender
Please rate your level of balance problems No imbalance o o o o o o o o o o o Severe imbalance
Please rate your level of sensitivity to loud No sensitivity o o o o o o o o o o o Extreme sensitivity 
noises, bright lights, odors, and cold
Scoring:
Step 1. Sum the scores for each of the three domains (function, overall, and symptoms).
Step 2. Divide domain 1 score by three, divide domain 2 score by one (that is, it is unchanged), and divide domain score 3 by two.
Step 3. Add the three resulting domain scores to obtain the total Revised Fibromyalgia Impact Questionnaire score.
Adapted from Bennett et al. (2009a).
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Most TCAs increase CNS levels of serotonin and norepinephrine 
by directly blocking their reuptake. Many TCAs bind to multiple 
receptors, and thus may have many adverse effects, especially at 
higher doses. In general, secondary amines (e.g., nortriptyline, 
desipramine) are tolerated somewhat better than tertiary amines 
(e.g., amitriptyline, imipramine, doxepin). Tolerability can be 
improved by starting at lower doses (e.g., 10 mg of amitriptyline 
or 5 mg of cyclobenzaprine), giving the dose shortly before bedtime, 
and gradually increasing the titration over time.
It appears that selective serotonin reuptake inhibitors (SSRIs) in 
general are poor agents in producing analgesia in most pain states. 
Highly SSRIs (e.g., citalopram) have not been shown to produce 
significant analgesia. Otto et al. (2008) conducted a randomized, 
double-blinded, placebo-controlled, cross-over trial to evaluate 
if escitalopram 20 mg would relieve pain in painful neuropathy. 
Total pain and various pain symptoms were reduced during the 
treatment (p = 0.001–0.024). The number needed to treat (NNT) 
to obtain good/complete pain relief was 6.8 (Otto et al., 2008). 
Otto demonstrated that escitalopram did possess pain-alleviating 
properties in painful neuropathy, but a clinically relevant effect 
was found in only a few patients. Therefore, he concluded that 
escitalopram should not be recommended as a standard treatment 
in neuropathic pain (Otto et al., 2008). SSRIs that are less selective 
for serotonin reuptake (e.g., fluoxetine, paroxetine, sertraline) may 
somewhat affect norepinephrine reuptake and provide some relief 
in FM, but at higher than average doses as they are less potent than 
TCAs or serotonin–norepinephrine reuptake inhibitors (SNRIs; 
Fishbain et al., 2000).
Most of the SNRIs clinically available for the treatment of FM 
have more of a significant impact on serotonin compared with 
norepinephrine activity. SNRIs tend to be better tolerated than 
older TCAs. Venlafaxine, the first SNRI available in the US, tends 
to have clinically significant effects on norepinephrine reuptake 
only when used at higher doses (Sayar et al., 2003).
Sayar et al. (2003) conducted a study to evaluate the efficacy of 
venlafaxine in the treatment of patients with FM. Fifteen patients 
with FM were assessed prior to and after treatment with fixed-dose 
venlafaxine 75 mg/day for 12 weeks. Primary endpoints were the 
FIQ total score and pain score. The authors found a significant 
improvement in the mean intensity of pain (F = 14.3; p = 0.0001) 
and in the disability caused by FM (F = 42.7; p = 0.0001). Thus, 
venlafaxine could potentially be beneficial in FM patients when 
used at these higher doses (Sayar et al., 2003).
Duloxetine and milnacipran are two SNRIs that are approved 
by the Food and Drug Administration (FDA) for the treatment of 
FM in the US (in 2008 and 2009, respectively).
Duloxetine inhibits serotonin reuptake significantly more than 
norepinephrine reuptake (in an approximate 10:1 ratio; Stahl 
et al., 2005). The standard dosing to aim for is 60 mg/day, which in 
selected patients can be increased to 120 mg/day based on respon-
siveness and tolerability. Duloxetine is the (+)-(S) isomer of the 
racemic mixture with structural similarities to both fluoxetine 
and atomoxetine (Smith and Barkin, 2010). It possesses a second-
ary amine structure unlike venlafaxine, the first approved SNRI, 
which possesses a tertiary amine structure. It has a usual half-life 
of 8–17 h. Its metabolic pathways include cytochrome P450 1A2 
and 2D6. Approximately 70% of duloxetine is renally excreted as 
Nishishinya et al. (2008) recently performed a systematic review 
specifically on the efficacy of amitriptyline in the treatment of FM. 
Ten RCTs were identified, and the overall study quality was moder-
ate to high (Nishishinya et al., 2008). Amitriptyline 25 mg/day (six 
RCTs) demonstrated a therapeutic response compared with pla-
cebo in the domains of pain, sleep, fatigue, and overall patient and 
investigator impression (Nishishinya et al., 2008). This benefit was 
generally seen at 6–8 weeks of treatment but no significant effect 
was observed at 12 weeks (Nishishinya et al., 2008). Amitriptyline 
50 mg/day (four RCTs) did not appear to demonstrate a signifi-
cant therapeutic effect compared with placebo (Nishishinya et al., 
2008). Neither dose of amitriptyline seemed to have an effect on 
tender point count (Nishishinya et al., 2008). The authors con-
cluded that there is some evidence to support the short-term effi-
cacy of amitriptyline 25 mg/day in FM (Nishishinya et al., 2008). 
However, there appeared to be no significant evidence to support 
the efficacy of amitriptyline at higher doses or for periods >8 weeks 
(Nishishinya et al., 2008).
Cyclobenzaprine is a centrally acting muscle relaxant which has 
a TCAs nucleus analog similar to amitriptyline and imipramine 
(Smith and Barkin, 2010; Figure 3). It exhibits norepinephrine 
and serotonin reuptake blockade as well as central and peripheral 
anticholinergic effects. The usual half-life is 32 h in capsules and 
18 h in tablets. Metabolism of cyclobenzaprine is by CYP 3A4, 1A2, 
and 2D6 (Smith and Barkin, 2010). Cyclobenzaprine has been used 
to treat the musculoskeletal component and improves sleep in FM 
patients (Goldenberg, 1989).
Tofferi et al. (2004) systematically reviewed the effectiveness of 
cyclobenzaprine in the treatment of FM. Five randomized, pla-
cebo-controlled trials were identified. Endpoints included global 
improvement, treatment effects on pain, fatigue, sleep, and ten-
der points over time. The odds ratio for global improvement with 
therapy was 3.0 [95% confidence interval (95% CI) 1.6–5.6] with 
a pooled risk difference of 0.21 (95% CI 0.09–0.34), which calcu-
lates to 4.8 (95% CI 3.0–11) individuals needing treatment for one 
patient to experience symptom improvement. Pain improved early 
on, but there did not appear to be any significant improvement 
in fatigue or tender points at any time. The authors concluded 
that cyclobenzaprine-treated patients were three times as likely to 
report overall improvement and to report moderate reductions 
in individual symptoms, particularly sleep (Tofferi et al., 2004).
N
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Figure 3 | Chemical structures of cyclobenzaprine (A), amitriptyline (B), 
and cyproheptadine (C).
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the FIQ total score, the PGI-I score, the CGI-I score, the mean of 
the tender points pain thresholds, the number of tender points 
with a low threshold (≤4 kg/cm2), and the SDS. Significant pain 
reduction was observed as assessed by numerous endpoints during 
the open-label phase of the study. This reduction in pain severity 
persisted throughout the double-blinded phase, as evidenced by 
additional mean decreases in the BPI average pain score within 
both duloxetine groups (Chappell et al., 2009a).
Another study conducted by Chappell et al. (2009b) analyzed 
the effectiveness of duloxetine (n = 162) compared with placebo 
(n = 168) in the treatment of FM patients for 6 months. It was 
a Phase III, parallel, double-blinded, placebo-controlled trial in 
which patients were initially randomized to duloxetine 60 mg/
day or placebo. The co-primary endpoints were BPI average pain 
score and the PGI-I score. The BPI average score and PGI-I score 
both demonstrated greater numerical improvement in duloxetine-
treated compared with placebo-treated groups, but the differences 
were not statistically significant (BPI average score p = 0.053, PGI-I 
p = 0.073). However, a significant treatment-by-investigator inter-
action was observed for these variables which could not be fully 
explained. Duloxetine-treated patients did improve significantly 
on secondary endpoints which can be considered important fac-
tors in assessing treatment efficacy in patients with FM (Chappell 
et al., 2009b).
Arnold et al. (2009) pooled data from four of the prior RCTs so 
as to enable the assessment of precise treatment effects. Changes 
in the BPI average pain severity scores demonstrated significantly 
greater improvement in duloxetine-treated vs. placebo-treated 
patients at week 1 and continuing through week 12 (p < 0.001). 
Duloxetine also showed significantly greater improvement com-
pared with placebo on the BPI severity scores for least pain, worst 
pain, and pain right now and on the mean of the pain interfer-
ence scores. Finally, duloxetine was statistically superior to placebo 
with respect to improvement in CGI-S scores (p < 0.001), FIQ 
total scores (p < 0.001), HAMD
17
 total scores (p = 0.003), PGI-I 
scores (p < 0.001), and QOL endpoints. The authors concluded that 
duloxetine 60–120 mg/day effectively improved FM symptoms and 
may offer benefits beyond pain relief, as evidenced by improvement 
in secondary endpoints (Arnold et al., 2009).
Choy et al. (2009) pooled data from the prior five RCTs to reli-
ably assess the safety and tolerability of duloxetine in the treat-
ment of patients with FM. The most commonly reported pooled 
treatment emergent adverse events (TEAEs) with duloxetine were 
nausea (33.4%), headache (25.2%), dry mouth (19.2%), insomnia 
(16.9%), fatigue (12.3%), constipation (16.7%), diarrhea (12.9%), 
and dizziness (15.1%). Most TEAEs were mild to moderate in sever-
ity and emerged early in treatment. About 20% of patients discon-
tinued due to TEAEs in both the short-term and 1-year studies. 
Serious adverse events (SAEs) were uncommon, and there were no 
significant differences in SAEs between groups. Mean changes in 
vital signs and weight were small. Although duloxetine’s noradren-
ergic effect suggests that it may slightly increase heart rate, only 
0.5% of patients in the 3- and 6-month studies, 0.1% of patients 
enrolled for 6 months or more, and 0.6% of patients in the 1-year 
study had a clinically relevant increase in pulse rate. Rates of clini-
cally significant laboratory and EKG changes were low, with the 
exception of ALT values being greater than five times the upper 
metabolites, with <1% as the parent compound. Metabolites found 
in plasma and urine include 4-hydroxy duloxetine glucuronide 
and 5-hydroxy, 6-methoxy duloxetine sulfate, neither of which 
appear to be significantly pharmacologically active (Curran, 2009). 
Approximately 20% of duloxetine is excreted in the feces, possibly 
representing hepatobiliary secretion. Duloxetine exhibits a high 
degree of protein binding (90%) and binds primarily to albumin 
and alpha-1-acid glycoprotein (Smith and Barkin, 2010).
Arnold et al. (2004) conducted a multicenter (18 centers), ran-
domized, double-blinded, placebo-controlled trial assessing the 
efficacy of duloxetine in FM patients with or without concurrent 
major depressive disorder (MDD). After single-blinded placebo 
treatment for 1 week, patients were randomized to either duloxet-
ine 60 mg twice daily (n = 104) or placebo (n = 103) for 12 weeks. 
Co-primary endpoints included the FIQ total score and FIQ pain 
score. Compared with placebo-treated subjects, duloxetine-treated 
subjects improved significantly more (p = 0.027) on the FIQ total 
score, but not significantly more on the FIQ pain score (p = 0.130). 
The FIQ pain score, however, might be limited in its capacity as an 
endpoint in that subjects must recall and rate their pain over the 
prior week, which may be more difficult to recall than pain over 
the past 24 h (Arnold et al., 2004).
Another multicenter (21 centers), randomized, double-blinded, 
placebo-controlled trial conducted by Arnold et al. (2005) assessed 
the efficacy of duloxetine exclusively in the treatment of females 
with or without MDD. The women were randomized to one of 
three treatment groups for a 12-week duration: duloxetine 60 mg/
day (n = 118), duloxetine 60 mg twice daily (n = 116), or placebo 
(n = 120). The primary endpoint was pain severity as measured by 
the BPI average pain severity score. Compared with placebo, both 
duloxetine-treated groups improved significantly more (p < 0.001) 
on the BPI average pain severity score. A significantly higher per-
centage of duloxetine-treated patients had a decrease of ≥30% in 
this score [duloxetine 60 mg/day (55%; p < 0.001); duloxetine 60 mg 
twice daily (54%; p = 0.002); placebo (33%); Arnold et al., 2005].
A third study conducted by Russell et al. (2008) also examined 
the efficacy of duloxetine for reducing pain severity in patients with 
or without current MDD over a 6-month period. It was a mul-
ticenter, randomized, double-blinded, placebo-controlled trial in 
which 520 patients were randomized to one of four groups: duloxe-
tine 20 mg/day, 60 mg/day, 120 mg/day, or placebo. The co-primary 
endpoints were the BPI average pain severity score and PGI-I score. 
Compared with placebo, patients treated with duloxetine 120 mg/
day improved significantly more on the co-primary endpoints at 
3 months [change in BPI score (−2.31 vs. 1.39, p < 0.001) and PGI-I 
score (2.89 vs. 3.39, p = 0.004)] and at 6 months [change in BPI score 
(−2.26 vs. 1.43, p = 0.003) and PGI-I score (2.93 vs. 3.37, p = 0.012)]. 
Compared with placebo, patients treated with duloxetine 60 mg/day 
also demonstrated significantly improved co-primary endpoints at 
3 months and BPI score at 6 months (Russell et al., 2008).
A study conducted by Chappell et al. (2009a) evaluated the effi-
cacy of duloxetine in FM over a 1-year period. It was a Phase III 
study which consisted of an 8-week open-label period followed 
by a 52-week double-blinded period. Patients received duloxetine 
30 mg/day for 1 week, then 60 mg/day for 7 weeks, and were sub-
sequently randomized to either 60 or 120 mg/day. The endpoints 
included the BPI average pain severity and interference item scores, 
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receiving milnacipran 200 mg/day during the lead-in study were 
maintained at this dose (n = 209). Patients initially assigned to 
placebo or milnacipran 100 mg/day were re-randomized to two 
groups: 100 mg/day (n = 48) or 200 mg/day (n = 192) of mil-
nacipran for an additional 6 months. Endpoints included visual 
analog pain ratings, FIQ total score, and PGI-C score. Patients 
continuing on milnacipran demonstrated a sustained reduction 
in pain over the entire 12-month period. Additional benefits were 
maintained as evidenced by FIQ and PGI-C scores. Patients initially 
assigned to placebo or milnacipran 100 mg/day and re-randomized 
to milnacipran 200 mg/day experienced further improvements in 
mean pain scores, FIQ total scores, and PGI-C scores at 1-year 
(Goldenberg et al., 2010).
Mease et al. (2009) performed a study which evaluated the effi-
cacy of milnacipran in the treatment of FM. It was a 27-week, 
double-blinded, multicenter trial in which 888 patients were ran-
domized to one of three groups: placebo, 100 mg/day, or 200 mg/
day of milnacipran. “FM responders” were considered 3-measure 
composite responders, while “FM pain responders” were consid-
ered 2-measure composite responders. After 3-month stable-dose 
treatment, a significantly higher percentage of milnacipran-treated 
patients met criteria as FM responders vs. placebo-treated patients 
(milnacipran 200 mg/day, p = 0.017; milnacipran 100 mg/day, 
p = 0.028). A significantly higher percentage of patients treated with 
milnacipran 200 mg/day also met criteria as FM pain responders 
vs. placebo-treated patients (p = 0.032). Significant pain reductions 
were observed after week 1 with both milnacipran doses (Mease 
et al., 2009).
Clauw et al. (2008) conducted a study which analyzed the effec-
tiveness of milnacipran for the treatment of FM over a 15-week 
period. It was a multicenter, double-blinded, placebo-controlled 
trial in which 1,196 patients were randomized to either placebo 
(n = 401), milnacipran 100 mg/day (n = 399), or 200 mg/day 
(n = 396). The two primary endpoints were rates of FM composite 
responders and FM pain composite responders. Compared with 
placebo, significantly greater proportions of milnacipran-treated 
subjects were FM composite responders (100 mg/day: p = 0.01; 
200 mg/day: p = 0.02) and FM pan composite responders (100 mg/
day: p = 0.03; 200 mg/day: p = 0.004). Furthermore, milnacipran 
was shown to significantly improve pain after 1 week of treatment 
(100 mg/day: p = 0.004; 200 mg/day: p = 0.04; Clauw et al., 2008).
Finally, Geisser et al. (2011) pooled results from two of the 
prior RCTs to determine more precise treatment effects for mil-
nacipran in FM. Once again the primary endpoints were a 2- and 
3-measure composite response analysis. Additionally, a pooled 
analysis of mean changes from baseline pain scores was conducted 
in order to evaluate the effectiveness of milnacipran over time. At 
3 months, composite responder rates were significantly higher in 
milnacipran-treated subjects compared with placebo-treated sub-
jects (2- and 3-measure composite responder analyses: p ≤ 0.001, 
both doses vs. placebo). These improvements were not dependent 
upon baseline pain severity. Similar composite responder results 
were observed in patients who continued treatment for up to 
6 months. Significant improvements in mean pain scores were 
seen with both doses of milnacipran compared with placebo 
as early as 1 week after treatment and were sustained for up to 
6 months (Geisser et al., 2011).
limit of normal in duloxetine-treated patients (0.6%) compared 
with placebo-treated patients (0%). However, the lack of cases that 
met criteria for Hy’s rule during either short- or long-term use 
suggests that the risk of hepatotoxicity for duloxetine in FM is very 
low. In the 1-year study, four patients (1.1%) had suicide-related 
behavior. However, without the presence of a placebo, this rate is 
difficult to interpret, especially because high rates of suicide have 
been demonstrated for patients with widespread pain syndromes 
like FM (Choy et al., 2009).
Milnacipran is the only currently FDA approved SNRI that inhib-
its norepinephrine reuptake more than serotonin reuptake. The 
standard dosing to aim for is 100 mg/day (50 mg BID), which in 
selected patients can be increased to 200 mg/day based on respon-
siveness and tolerability. Milnacipran is a chiral compound with an 
active portion being the d-isomer (Smith and Barkin, 2010). The 
usual half-life of milnacipran is 6–8 h for the parent compound and 
8–10 h for d-milnacipran, the active isomer; thus twice-daily dosing 
is recommended. Milnacipran’s metabolism has a limited hepatic 
contribution and is eliminated primarily by glucuronidation to an 
inactive metabolite. Elimination is predominantly renal (50–60% as 
unchanged parent compound in urine) with a small amount excreted 
in the feces (5% or less; Smith and Barkin, 2010). Early studies dem-
onstrated milnacipran’s efficacy for treating pain and other associated 
symptoms of FM (Vitton et al., 2004; Gendreau et al., 2005).
Arnold et al. (2010) conducted a study assessing the efficacy of 
milnacipran for the treatment of FM. It was a 12-week, double-
blinded, placebo-controlled trial in which 1,025 patients were rand-
omized to milnacipran 100 mg/day (n = 516) or placebo (n = 509). 
Patients underwent 4–6 weeks of flexible-dose escalation followed 
by 12 weeks of stable-dose treatment. Two composite responder 
definitions were utilized as primary endpoints. The 2-measure 
composite responders achieved ≥30% improvement in pain and a 
rating of “very much improved” or “much improved” on the PGI-C 
(Change) scale. The 3-measure composite responders satisfied the 
above criteria while also demonstrating improvement on the SF-36 
Physical Component Summary score. A significantly greater pro-
portion of milnacipran-treated patients compared with placebo-
treated patients showed statistically significant improvements, as 
evidenced by 2-measure composite responder criteria (p < 0.001) 
and 3-measure composite responder criteria (p < 0.001; Arnold 
et al., 2010).
Branco et al. (2010) performed a randomized, double-blinded, 
placebo-controlled, multicenter study examining the effectiveness 
of milnacipran in the treatment of FM. Eight hundred eighty-four 
patients were randomized to placebo (n = 449) or milnacipran 
200 mg/day (n = 435) for 17 weeks. The primary endpoint was a 
2-measure composite responder analysis. If the responder analysis 
was positive, FIQ was included as an additional primary endpoint. 
At the end of week 16, milnacipran 200 mg/day showed significant 
improvements compared with placebo in the 2-measure composite 
responder criteria (p = 0.0003) and FIQ total score (p = 0.015; 
Branco et al., 2010).
In an article by Goldenberg et al. (2010) the authors wanted to 
assess the durability of the therapeutic response to milnacipran for 
FM via a randomized, double-blinded, 6-month extension study. A 
total of 449 patients who successfully completed a 6-month lead-in 
study enrolled in this 6-month extension study. Patients initially 
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seventy-four (61%) placebo patients met LTR criteria compared 
with 90 (32%) pregabalin patients at the end of the double-blinded 
phase (Crofford et al., 2008).
Mease et al. (2008) conducted a study which examined the 
efficacy of pregabalin for symptomatic pain relief and for the 
management of FM. It was a multicenter, double-blinded, placebo-
controlled trial in which 748 FM patients were randomized to pla-
cebo, pregabalin 300, 450, or 600 mg/day for 13 weeks. The primary 
endpoint for symptomatic pain relief was comparison of mean 
pain scores among each pregabalin group and placebo. The pri-
mary endpoint for management of FM included mean pain scores, 
PGI-C score, and FIQ total score. Patients in all pregabalin groups 
demonstrated statistically significant improvement in mean pain 
score and in PGI-C score compared with placebo. Improvements 
in FIQ total score were numerically but not significantly greater 
than those for placebo (Mease et al., 2008).
Arnold et al. (2008) conducted an RCT which analyzed the 
effectiveness of pregabalin monotherapy in patients with FM. 
After 1 week of single-blinded placebo therapy, 750 patients were 
randomized to placebo, pregabalin 300, 450, or 600 mg/day for 
14 weeks The primary endpoint was comparison of mean pain 
scores, derived from daily diary ratings of pain intensity on a 
0–10 scale, among each of the pregabalin groups and placebo. If 
positive, additional primary endpoints included the PGI-C score 
and the FIQ total score. Compared with placebo-treated subjects, 
mean changes in pain scores in pregabalin-treated subjects were 
significantly greater (p < 0.001: 300 mg/day, −0.71; 450 mg/day, 
−0.98; 600 mg/day, −1.00). Compared with placebo, significantly 
more pregabalin-treated subjects reported improvement in PGI-C 
score (p < 0.01 for all three doses) and significant improvements 
in FIQ total score for the 450-mg/day (p = 0.004) and 600-mg/day 
(p = 0.003) doses (Arnold et al., 2008).
Finally, Straube et al. (2010) performed a meta-analysis of five 
pregabalin trials (n = 3,808) in FM utilizing company trial reports. 
Significant benefit of pregabalin over placebo was seen for a variety 
of endpoints including mean pain and sleep scores, the proportion 
of patients achieving at least 50% pain reduction, and most of the 
individual domains of short form 36.
The meta-analysis demonstrated that pregabalin-treated 
patients (≥300 mg/day) experienced more somnolence, dizziness, 
>7% weight gain, and discontinuations due to adverse events com-
pared with placebo-treated patients. For dizziness and discontinu-
ation due to adverse events there was a significant dose–response 
relationship. For somnolence, nausea, and weight gain there was 
no significant dose dependence. There was no significant difference 
between pregabalin and placebo in the rate of SAEs (approximately 
2% in each case; Straube et al., 2010).
As of yet, there have not been any direct head-to-head com-
parisons of the three FDA approved drugs for FM. Häuser et al. 
(2010), however, recently compiled data from 11 RCTs enrolling 
6,388 patients, which indirectly compared the benefits and harms 
of duloxetine, milnacipran, and pregabalin specifically in FM. The 
endpoints analyzed were reductions in pain, fatigue, sleep distur-
bance, depressed mood, HRQOL, and adverse events. They found 
that all three drugs were superior to placebo except for the following 
symptom-types: duloxetine for fatigue, milnacipran for sleep dis-
turbances, and pregabalin for depressed mood. Häuser et al. (2010) 
In the pooled analysis of data the most commonly reported 
adverse events with milnacipran treatment were nausea (100 mg/
day 34.5%, 200 mg/day 40.1%, placebo 20.4%), headache 
(100 mg/day 18.6%, 200 mg/day 18.3%, placebo 14.1%), and 
constipation (100 mg/day 16.2%, 200 mg/day 16.1%, placebo 
4.0%; Geisser et al., 2011). Greater than 90% of the adverse events 
reported in each treatment group were classified as either mild 
or moderate in severity. Furthermore, milnacipran treatment 
did result in slight increases in heart rate (100 mg/day 5.5%, 
200 mg/day 6.5%, placebo 1.1%) and blood pressure (100 mg/
day 6.6%, 200 mg/day 4.5%, placebo 1.9%). Patients at 6-month 
visits who received milnacipran 100 and 200 mg/day tended to 
lose more weight (−1.16 and −0.97 kg, respectively) compared 
with patients receiving placebo (−0.06 kg; p < 0.05, both doses 
vs. placebo; Geisser et al., 2011).
Pregabalin, approved for the treatment of FM in the US in 2007, 
is a gamma-aminobutyric acid (GABA) analog which binds to the 
alpha-2-delta subunit of calcium ion channels. The half-life of 
pregabalin is 5.5–6.7 h in the presence of a normal CrCl (Smith 
and Barkin, 2010). The dosing for this agent, however, is depend-
ent upon the patient’s CrCl because elimination is a function of 
renal clearance. Decremental dosing changes are recommended in 
patients with impaired renal function. Dosing secondary to side 
effects is based on 1-week intervals focusing on patient responsive-
ness and tolerability. Pregabalin’s metabolism is negligible (not by 
CYP450 or Phase II metabolism; Barkin, 2008). Its metabolite is an 
N-methylated derivative. It is renally excreted, with 98% or greater 
as the unchanged parent compound. No plasma protein binding 
has been reported (Smith and Barkin, 2010).
Crofford et al. (2005) conducted a study in which the efficacy 
of pregabalin for the treatment of FM was evaluated. It was a mul-
ticenter, double-blinded, placebo-controlled trial in which 529 
patients were randomized to one of four groups for 8 weeks: pla-
cebo, pregabalin 150, 300, and 450 mg/day. The primary endpoint 
was the comparison of end point mean pain scores, derived from 
daily diary ratings of pain intensity, among each of the pregabalin 
groups and the placebo group. Pregabalin 450 mg/day significantly 
reduced the average severity of pain in the primary analysis com-
pared with placebo (−0.93 on a 0–10 scale; p ≤ 0.001), and sig-
nificantly more patients in this group had ≥50% improvement in 
pain at the end point (29 vs. 13% in the placebo group; p = 0.003; 
Crofford et al., 2005).
In the FREEDOM study performed by Crofford et al. (2008) pre-
gabalin’s efficacy of durability was assessed in a multicenter, dou-
ble-blinded, placebo-controlled, 32-week trial. The trial included 
a 6-week open-label phase followed by a 26-week double-blinded 
phase. During open-label weeks 1–3, patients received escalat-
ing doses of pregabalin to determine their optimal doses. During 
open-label weeks 4–6, patients received their optimal fixed doses 
(i.e., 300, 450, 600 mg/day). Two hundred eighty-seven patients 
were randomized to placebo, and 279 patients were randomized to 
pregabalin. The primary endpoint was time to loss of therapeutic 
response (LTR), defined as <30% reduction in pain or worsen-
ing of FM. Time to LTR was longer for pregabalin compared with 
placebo (p < 0.0001). Kaplan–Meier estimates of time-to-event 
showed half the placebo group had LTR by day 19; half the prega-
balin group still had not lost response by trial end. One hundred 
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FM patients (Holman and Myers, 2005). Tizanidine is a centrally 
acting alpha-2-adrenergic agonist that may possess muscle-relaxing 
effects in patients with spasticity. Tizanidine potentially may pro-
vide benefit for FM patients by reductions in pain, improvement 
in sleep, and improvement in QOL measures (Russell et al., 2002). 
Furthermore, tizanidine treatment reduced substance P levels in 
the CSF of FM patients.
Tramadol is a compound that possesses weak analgesic effects 
by binding to mu-opioid receptors, but its major pain-relieving 
effects are through serotonin–norepinephrine reuptake inhibi-
tion. The activity of the drug is focused on the M1 metabolite 
(O-desmethyltramadol), which yields six times more potent anal-
gesia than the parent compound. The usual half-life of tramadol 
is 8 and 9 h for the M1 metabolite. It is metabolized by CYP450 
enzymes 2B6, 2D6, and 3A4 (Smith and Barkin, 2010). Tramadol 
seems to be beneficial for the treatment of FM both alone and as a 
fixed-dose combination with acetaminophen (Russell et al., 2000; 
Bennett, 2001; Bennett et al., 2003).
Tapentadol is an agent that has not yet been studied for the 
treatment of FM. It does, however, possess some opioid effects 
as well as inhibits the reuptake of norepinephrine. Tapentadol 
exhibits extensive hepatic first pass effects, and its metabolism is 
largely hepatic primarily by the Phase II pathway (85%; glucuro-
nidation, conjugation) and minor (15%) Phase I CYP450 oxida-
tion (2C9), 2C19 (13%), 2D6 (2%). Thus there is minimal risk of 
any CYP450 drug interactions (Smith and Barkin, 2010). Non-
analgesic N-desmethyl and OH-tapentadol metabolites follow with 
metabolism by conjugation (Smith and Barkin, 2010). Phase II 
metabolism is a high-capacity/low-affinity system providing water 
soluble, inactive metabolites for renal elimination. Tapentadol is 
99% renally excreted: 70% as inactive metabolites and only 3% 
as the parent compound. It has a plasma protein binding of 20% 
and thus no significant plasma protein-binding interactions (Smith 
and Barkin, 2010).
Ultimately the management of FM can be approached in a step-
wise manner, utilizing the most tried and true strategies initially 
and resorting to less well-studied agents with potential side effects 
based on individual patient responsiveness. This may be illustrated 
by a potential speculative schematic which represents a “step-lad-
der” type approach to the clinical management of FM (Smith and 
Barkin, 2010; Figure 4).
CONCLUSION
Fibromyalgia is a disorder characterized by CWP as well as other 
somatic symptoms. It appears to impart marked morbidity, nega-
tively impacting physical functioning, HRQOL, sleep, emotional 
health, and social well-being, thus requiring prompt diagnosis 
and treatment. Non-FDA approved agents, such as amitriptyl-
ine and cyclobenzaprine, have been utilized in the “off-label” 
management of FM. There is evidence to support the short-term 
use of amitriptyline 25 mg/day, but higher doses for longer peri-
ods do not appear to be efficacious (Nishishinya et al., 2008). 
Cyclobenzaprine, which is structurally similar to amitriptyline, 
seems to be effective for the musculoskeletal component and 
improves sleep (Goldenberg, 1989). Agents such as SSRIs (Otto 
et al., 2008) and opioids appear to demonstrate little efficacy in 
FM. The three FDA approved agents, pregabalin, duloxetine, and 
found the pooled NNTs for a 30% pain reduction to be as follows: 
duloxetine 7.2, milnacipran 19, and pregabalin 8.6. The authors 
showed that there was no significant difference among the three 
drugs in achieving a minimum 30% reduction in pain and dis-
continuation rates due to adverse events were similar (Häuser 
et al., 2010). There were substantial differences in symptom-type 
alleviated and adverse effects produced for each particular drug. 
Duloxetine and pregabalin were superior to milnacipran for pain 
and sleep disturbance. Duloxetine was superior to milnacipran and 
pregabalin for depressed mood. Milnacipran and pregabalin were 
superior to duloxetine for fatigue. The risk of headache and nau-
sea was higher with duloxetine and milnacipran compared with 
pregabalin. The risk of diarrhea was higher with duloxetine com-
pared with milnacipran and pregabalin. The most frequent adverse 
effects noted in pregabalin-treated patients were weight gain and 
peripheral edema. Rare but SAEs reported were liver failure and 
suicidality for duloxetine and milnacipran, and heart failure for 
pregabalin. Häuser et al. (2010) found the numbers needed to harm 
(NNHs) for discontinuation due to adverse effects to be as follows: 
duloxetine 14.9, milnacipran 7.6, and pregabalin 7.6.
Gabapentin is another alpha-2-delta ligand and antiepileptic 
drug structurally similar to pregabalin, but not approved for the 
treatment of FM. Its usual half-life is 5–7 h in normal renal function. 
Gabapentin is almost entirely eliminated renally as the parent com-
pound as a result of negligible metabolism and requires renal dosing 
(Smith and Barkin, 2010). Despite not being approved, this agent 
has shown potential benefit in clinical trials. Arnold et al. (2007) 
performed a randomized, double-blinded, placebo-controlled trial 
examining the effectiveness/safety of gabapentin in treating FM. 
Patients were randomized to either gabapentin 1,200–2,400 mg/day 
(n = 75) or placebo (n = 75) for 12 weeks. The primary endpoint 
was the BPI average pain severity score. The authors concluded 
that gabapentin 1,200–2,400 mg/day is safe and efficacious for the 
treatment of pain and other symptoms associated with FM (Arnold 
et al., 2007).
Gamma-hydroxybutyrate (also known as sodium oxybate), a 
precursor of GABA known to possess strong sedative qualities, 
has been shown to improve fatigue, pain, and sleep architecture 
in FM (Scharf et al., 2003). Russell et al. (2009) randomized 118 
patients with FM (92 of which completed the study) after dis-
continuing their pre-study FM medications to receive 4.5 or 6.0 g 
of sodium oxybate or placebo once per night for 8 weeks. The 
primary endpoint was a composite score in three co-primary self-
reported measures: patient’s pain rating (in daily electronic dair-
ies) on a visual analog scale, the FIQ score, and the PGI-C score. 
Significant benefit was observed with both doses of sodium oxybate 
with regards to changes in the primary endpoint and subjective 
sleep quality. Improvements in patient pain ratings correlated well 
with sleep outcomes. Sodium oxybate was well-tolerated overall, 
with dose-related nausea (≤28% of patients) and dizziness (≤18% 
of patients) resolving with continued therapy (Russell et al., 2009).
Though speculative, it is conceivable that agents such as prami-
pexole and tizanidine may possess beneficial effects for patients with 
FM and co-existing restless leg syndrome or spasticity, respectively. 
Pramipexole is a dopamine agonist utilized for Parkinson’s dis-
ease that is also useful for the treatment of restless leg syndrome 
(Bennett, 2001). Pramipexole may improve both pain and sleep in 
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for FM patients with concomitant restless leg syndrome (Bennett, 
2001; Holman and Myers, 2005). Tramadol, which possesses some 
analgesic activity, may be utilized for FM patients with a significant 
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